1338577-20-0

Basic information

• Product Name: 3-O-[(E)-(2-oxo-4-(p-tolyl) but–3–en–1–yl)]kaempferol
• Synonyms: 3-O-[(E)-(2-oxo-4-(p-tolyl) but–3–en–1–yl)]kaempferol
• CAS NO: 1338577-20-0
• Molecular Weight: 444.441
• Mol File: 1338577-20-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 3-O-[(E)-(2-oxo-4-(p-tolyl) but–3–en–1–yl)]kaempferol(CAS DataBase Reference)
• NIST Chemistry Reference: 3-O-[(E)-(2-oxo-4-(p-tolyl) but–3–en–1–yl)]kaempferol(1338577-20-0)
• EPA Substance Registry System: 3-O-[(E)-(2-oxo-4-(p-tolyl) but–3–en–1–yl)]kaempferol(1338577-20-0)

Safety Data

• Hazardous Substances Data: 1338577-20-0(Hazardous Substances Data)

Upstream product

• 1357162-53-8 (E)-1-bromo-4-(p-tolyl) but-3-en-2-one 
• 520-18-3 kaempferol 
• 104-87-0 4-methyl-benzaldehyde 
• 4023-84-1 4-(p-tolyl)-3-buten-2-one 
• 1219923-45-1 C₁₁H₁₁BrO 

Relevant articles and documents

The tiliroside derivative, 3-O-[(E)-(2-oxo-4-(p-tolyl) but–3–en–1–yl] kaempferol produced inhibition of neuroinflammation and activation of AMPK and Nrf2/HO-1 pathways in BV-2 microglia

Neuroinflammation is now widely accepted as an important pathophysiological mechanism in neurodegenerative disorders, thus providing a critical target for novel compounds. In this study, 3-O-[(E)-(2-oxo-4-(p-tolyl)but-3-en-1-yl] kaempferol (OTBK) prevente

Synthesis and biological activity of novel tiliroside derivants

A series of new tiliroside derivatives were synthesized and characterized by analytical 1H NMR, 13C NMR and mass spectrometry. All of the compounds were evaluated for anti-diabetic properties in vitro using HepG2 cells. Compounds 3c, 3d, and 3i-l caused significant enhancements in glucose consumption by insulin-resistant HepG2 cells compared with control cells and cells that were exposed to metformin (an anti-diabetic drug). Moreover, compound 3l significantly activated adenosine 5′-monophosphate-activated protein kinase activity and reduced acetyl-CoA carboxylase activity. Thus, the tiliroside derivative 3l offers potential to be developed as a new approach for treating type II diabetes.